From what Gary said in the conference call it seems like they are seeing some real big gains in visual function in the later stage patients that were injected with the higher dose. Thus he talked about running a couple different protocols for phase 2; earlier and later stage patients. In order to help determine what the RPE injections are indicated for, rescue versus preservation of vision. This is some fantastic news!
Nah, if there were truly positive news, there'd be no "seems like". The April injections get a 6 week check-up and we ain't even there yet. No real news about this until fall I'm afraid. However, the company used a ton of money for these trials..
Net cash used in operations for the 2013 first quarter was $8.3 million, compared to net cash used in operations of $4.8 million during the same period in 2012. The Company ended the 2013 first quarter with cash and cash equivalents of $4.1 million, compared to $7.2 million as of December 31, 2012, primarily due to higher operating expenses. Cash utilization increased significantly as a result of $2.3 million used to settle litigation related to previously issued debentures. The Company expects cash utilization to return to previous levels in the subsequent quarter.
There is no evidence of this and that would be filling the void with yet to be seen results. The move towards Phase II studies is to see the indication range of the treatment. But I do agree that if Phase II shows actual sight improvement beyond current Phase I and 2a then we may be closer to "compassionate use" which changes the revenue dynamics for ACTC dramatically---basically a 180% improvement if that happens. Also, chances of driving a firm and tough JV deal becomes more and more doable as they prove up the scientific outcomes to verify revenue potential.